Herantis Pharma – equity proposition

Herantis Pharma – equity proposition

Herantis Pharma — 5 videos in collection

More on this equity

Herantis Pharma is a clinical-stage biotechnology company based in Finland, focused on developing disease-modifying therapies for neurodegenerative diseases. Its lead candidate, HER-096, is being developed for Parkinson’s disease (PD) and has been designed to target the underlying biology of the condition, rather than just its symptoms.

We highlight four key reasons why Herantis may be considered a compelling investment opportunity.

  1. HER-096 represents a differentiated approach to PD.
  2. Early clinical data provide encouraging validation of the programme.
  3. Upcoming milestones provide catalysts for value creation.
  4. The programme addresses a sizeable and growing commercial opportunity.

For further details, please refer to our latest research on Herantis Pharma.


You may also be interested in these:

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.